Lithobid

(Lithium)

ApprovedSmall molecule

Lithium is used to treat bipolar disorder by helping to stabilize mood swings and reduce the severity of manic episodes. It can also be used to help prevent suicide in people with mood disorders.[2] Lithobid is currently approved and in use across 13 indications[4].[1]

Lithobid is one of 334 small molecule programs targeting Cognitive impairment. It is currently in Approved.

Indications

Total Trials

Active Trials

333

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Cognitive ImpairmentCompleted

SuicideActive, not recruiting

Osteoporosis - PseudogliomaActive, not recruiting

Fragile X SyndromeApproved

PsychosisActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Major Depressive DisorderRecruiting

Bipolar DisorderCompleted

CARCompleted

ESSCompleted

Cognitive ImpairmentApproved

Completed

SuicidePreclinical

Active, not recruiting

Osteoporosis - PseudogliomaPreclinical

Active, not recruiting

Fragile X SyndromeApproved

Approved

PsychosisApproved

Active, not recruiting

Small Cell Lung CancerPreclinical

Active, not recruiting

Major Depressive DisorderPhase 3

Recruiting

Bipolar DisorderApproved

Completed

CARPreclinical

Completed

ESSPreclinical

Completed

Showing 10 of 13 indications

Competition

Competitive Landscape

140 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

29 2

Tecentriq

Roche

Phase 3

26 3

Camptosar

Pfizer

Phase 3

26 4

Keytruda

Merck & Co.

Phase 3

19 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

97 6

Vepesid

Opdivo

14 8

Tarlatamab-Dznl

Amgen

Phase 3

11 9

Yervoy

Lynparza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Mania

NCT07140913

Q2 2028

Phase 3Recruiting

Bipolar Disorder

NCT06929273

Phase 3Recruiting

First-Line Treatment

NCT05973786

Phase 3Recruiting

Major Depressive Disorder

NCT05603104

Q3 2028

ApprovedRecruiting

Depression, Bipolar

NCT05913947

Q3 2033

Phase 2Recruiting

Cognitive Impairment

NCT06051240

Clinical

Trials by Indication[1]

Bipolar Disorder20 trials

Safety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder

Withdrawn·LLawson, William B., M.D., PhD, DFAPA·Phase 4·NCT01075126·50 enrolled

Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 3·NCT00194129·31 enrolled

Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder

Unknown status·UUniversity of Cincinnati·Phase 4·NCT00608075·260 enrolled

Show 17 more trials

Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

Completed·NNew York State Psychiatric Institute·Phase 1·NCT00563992·98 enrolled

Decision-Making in Bipolar Disorder

Completed·EEmory University·N/A·NCT01463111·37 enrolled

Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00672490·376 enrolled

PET and MRI Brain Imaging of Bipolar Disorder

Completed·SStony Brook University·N/A·NCT01880957·76 enrolled

Treatment and Outcome of Early Onset Bipolar Disorder

Completed·NNorthwell Health·Phase 4·NCT00048802·40 enrolled

Combination Therapy for the Treatment of Bipolar Disorders

Terminated·UUniversity Hospitals Cleveland Medical Center·Phase 3·NCT00063362·49 enrolled

Sequential Multiple Assignment Treatment for Bipolar Disorder

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT01588457·112 enrolled

Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder

Withdrawn·EEwha Womans University·Phase 4·NCT01543724

Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder

Completed·—·Phase 3·NCT00221429·153 enrolled

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

Completed·NNational Institute of Mental Health (NIMH)·N/A·NCT00012558·5,000 enrolled

Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00448578·150 enrolled

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00114686·350 enrolled

Comparative Effectiveness Study for Bipolar Disorder

Completed·MMassachusetts General Hospital·Phase 4·NCT01331304·482 enrolled

Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide

Terminated·NNova Scotia Health Authority·Phase 3·NCT00400088·2 enrolled

FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder

Completed·IIndiana University·Phase 4·NCT00596622·46 enrolled

A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06929273·450 enrolled

Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder

Completed·BBrigham and Women's Hospital··NCT03336918·81 enrolled

Depression7 trials

Lithium and Standard Therapy in Resistant Depression

Unknown status·UUniversita di Verona·Phase 4·NCT00927550·230 enrolled

Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)

Completed·TTadashi Hasegawa·Phase 4·NCT02287259·50 enrolled

PRASED - Preventing Relapse After Successful Electroconvulsive Therapy for Depression

Active, not recruiting·UUniversiteit Antwerpen·N/A·NCT06751875·109 enrolled

Show 4 more trials

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

Completed·NNational Institute of Mental Health (NIMH)·Phase 4·NCT00021528·4,000 enrolled

Wake Therapy in the Treatment of Depression

Completed·NNew York State Psychiatric Institute·N/A·NCT01431573·8 enrolled

Optimizing Electroconvulsive Therapy for Depression

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00045916·340 enrolled

Acute Treatment of Bipolar II Depression

Completed·SStanford University·Phase 3·NCT00074776·102 enrolled

Bipolar I Disorder4 trials

Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00266630·139 enrolled

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

Completed· Otsuka logo

Otsuka·Phase 3·NCT00665366·493 enrolled

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00107731·710 enrolled

Show 1 more trial

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00081380·710 enrolled

Treatment Resistant Depression4 trials

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

Withdrawn·—·Phase 2·NCT03290963

Ketamine Plus Lithium in Treatment-Resistant Depression

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT01880593·34 enrolled

Lithium Versus Quetiapine in Treatment Resistant Depression

Unknown status·KKing's College London·Phase 4·NCT03004521·276 enrolled

Show 1 more trial

Interpersonal Psychotherapy for Treatment Resistant Depression

Unknown status·HHospital de Clinicas de Porto Alegre·N/A·NCT01896349·74 enrolled

Mood Disorder3 trials

Cost- Effectiveness and Quality of Life Assessment in Mood Disorder

Completed·FFederal University of Rio Grande do Sul·Phase 4·NCT02870283·107 enrolled

Lithium for Suicidal Behavior in Mood Disorders

Terminated·VVA Office of Research and Development·Phase 2/3·NCT01928446·519 enrolled

Characterization and Pathophysiology of Severe Mood and Behavioral Dysregulation in Children and Youth

Recruiting·NNational Institute of Mental Health (NIMH)··NCT00025935·2,350 enrolled

41 more indications

Major Depression3 trials

Lithium Versus Paroxetine in Major Depression

Withdrawn·NNova Scotia Health Authority·Phase 4·NCT01416220

Continuation Ketamine in Major Depression

Completed·JJames Murrough·Phase 1·NCT00548964·36 enrolled

Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder

Completed·FFederal University of Rio Grande do Sul·Phase 4·NCT02901249·68 enrolled

Bipolar Depression2 trials

Algorithm Guided Treatment Strategies for Bipolar Depression

Unknown status·SShanghai Mental Health Center·Phase 4·NCT01938859·360 enrolled

Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania

Completed·IIndiana University School of Medicine·Phase 4·NCT00457054·60 enrolled

Suicide2 trials

Treatment of Adolescent Suicide Attempters (TASA)

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT00080158·120 enrolled

Suicide Prevention by Lithium - the Lithium Intervention Study

Terminated·UUniversity Hospital Schleswig-Holstein·N/A·NCT00520026·167 enrolled

CAR2 trials

Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions

Completed·RRoxane Laboratories·N/A·NCT00601575·30 enrolled

Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions

Completed·RRoxane Laboratories·N/A·NCT00602394·30 enrolled

Fasting Conditions2 trials

Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions

Completed·RRoxane Laboratories·N/A·NCT00601536·29 enrolled

Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting Conditions

Completed·RRoxane Laboratories·N/A·NCT00602381·30 enrolled

Cognitive impairment2 trials

Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study

Completed·FFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia·Phase 4·NCT01348282·33 enrolled

Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy

Recruiting·RRegion Stockholm·Phase 2·NCT06051240·84 enrolled

Treatment2 trials

Pharmacotherapy of Treatment-Resistant Mania

Completed·UUniversity of Pittsburgh·Phase 3·NCT00518947·45 enrolled

Treatment of Bipolar Mania in Older Adults

Completed·WWeill Medical College of Cornell University·Phase 4·NCT00254488·224 enrolled

Phase 11 trial

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT00820794

First-line Treatment1 trial

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting·—·Phase 3·NCT05973786·418 enrolled

Aripiprazole1 trial

Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients

Unknown status·UUniversity of Sao Paulo·Phase 4·NCT01710163·50 enrolled

Randomised Controlled Trial1 trial

Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression

Completed·ÖÖrebro County Council·Phase 4·NCT00627887·56 enrolled

Amyotrophic Lateral Sclerosis1 trial

Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00925847·23 enrolled

Depressive Disorder1 trial

Electroconvulsive Therapy and Concomitant Lithium in Depressive Disorder: A Pilot Study

Unknown status·MMelbourne Health·Phase 1·NCT05923476·20 enrolled

Combination Therapy1 trial

Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 3·NCT00221975·98 enrolled

Tics1 trial

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

Completed·KKaruna Therapeutics·Phase 1·NCT06729970·133 enrolled

Agitation1 trial

Treatment of Psychosis and Agitation in Alzheimer's Disease

Completed·NNew York State Psychiatric Institute·Phase 2·NCT02129348·77 enrolled

Alzheimer's Disease1 trial

Effect of Lithium and Divalproex in Alzheimer's Disease

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00088387·35 enrolled

Prevention1 trial

Relapse Prevention for Bipolar Type-II Disorder

Completed·UUniversity of Pennsylvania·Phase 4·NCT00044616·180 enrolled

Conduct Disorder1 trial

Long-Term Lithium Treatment for Aggressive Conduct Disorder

Completed·—·Phase 3·NCT00000385·59 enrolled

Maintenance Treatment1 trial

Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode

Completed·UUniversity of British Columbia·Phase 3·NCT01977300·159 enrolled

Huntington's Disease1 trial

Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00095355·35 enrolled

Suicidality1 trial

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation

Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT01134731·54 enrolled

TIA1 trial

Gao Bipolar Spectrum Lithium/Quetiapine Study

Terminated·UUniversity Hospitals Cleveland Medical Center·Phase 4·NCT01526148·42 enrolled

Function1 trial

Functional and Neurochemical Brain Changes in First-episode Bipolar Mania

Completed·UUniversity of Cincinnati··NCT00609193·81 enrolled

Long COVID1 trial

Effect of Lithium Therapy on Long COVID Symptoms

Completed·SState University of New York at Buffalo·Phase 2·NCT05618587·52 enrolled

Major Depressive Disorder1 trial

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting·—·Phase 3·NCT05603104·1,254 enrolled

Effectiveness1 trial

A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study

Terminated· AstraZeneca logo

AstraZeneca·Phase 4·NCT01254721·131 enrolled

Parkinson's Disease1 trial

Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.

Completed·SState University of New York at Buffalo·Phase 1·NCT04273932·19 enrolled

Drug Therapy1 trial

Treatment of Mania Symptoms With Drug Therapy

Completed·PPalo Alto Veterans Institute for Research·Phase 3·NCT00183443·75 enrolled

Progressive Supranuclear Palsy1 trial

A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration

Completed·WWestat·Phase 1/2·NCT00703677·17 enrolled

Adult1 trial

Adult Bipolar Mania

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00931723·356 enrolled

Metabolism1 trial

Lithium Therapy: Understanding Mothers, Metabolism and Mood

Completed·NNorthwestern University··NCT02490241·9 enrolled

Colorectal Cancer1 trial

Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer

Terminated·CCancer Trials Ireland·Phase 1·NCT03153280·2 enrolled

Acceptability1 trial

Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

Unknown status·GGuiyun Xu·Phase 4·NCT01893229·120 enrolled

Osteoporosis-Pseudoglioma Syndrome1 trial

Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome

Completed·UUniversity of Maryland, Baltimore·N/A·NCT01108068·26 enrolled

ESS1 trial

Lithium Effects on Reward Processing and Reappraisal in Healthy Volunteers

Completed·UUniversity of Oxford·N/A·NCT03965247·37 enrolled

Olanzapine1 trial

Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features

Completed·MMelbourne Health·Phase 4·NCT00202293·83 enrolled

Small Cell Lung Cancer1 trial

A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer

Terminated·BBarwon Health·N/A·NCT01486459·7 enrolled

Mania1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT07140913·424 enrolled

Depression, Bipolar1 trial

Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression: a Pragmatic Head-to-head Open, Randomized Multicenter Study: The 9th Study of the Danish University Antidepressant Group (DUAG 9)

Recruiting·AAalborg University Hospital·Approved·NCT05913947·122 enrolled

Unspecified5 trials

Gao NARASD Lithium Study

Terminated·KKeming Gao·Phase 4·NCT02909504·24 enrolled

Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord

Completed·CChina Spinal Cord Injury Network·Phase 1/2·NCT01046786·8 enrolled

Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium

Completed·UUniversity of Sao Paulo·Phase 4·NCT01919892·30 enrolled

Show 2 more trials

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Lithium Versus Anticonvulsants and the Risk of Physical Disorders

Completed·—··NCT06005155·169,285 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 27, 1979

LITHOBID

NDA NDA018027

Oct 3, 1979

LITHOBID

NDA NDA018027

Oct 3, 1979

LITHOBID

NDA NDA018027

Oct 3, 1979

LITHOBID

NDA NDA018027

Jan 4, 1980

LITHOBID

NDA NDA018027

May 13, 1980

LITHOBID

NDA NDA018027

Oct 2, 1980

LITHOBID

NDA NDA018027

Apr 6, 1981

LITHOBID

NDA NDA018027

Aug 6, 1981

LITHOBID

NDA NDA018027

Sep 25, 1981

LITHOBID

NDA NDA018027

Jan 1, 1982

LITHONATE

NDA NDA017672

Jan 1, 1982

LITHIUM CITRATE

NDA NDA018421

Feb 19, 1982

LITHOBID

NDA NDA018027

Apr 19, 1982

LITHOBID

NDA NDA018027

Feb 25, 1983

LITHOBID

NDA NDA018027

Feb 25, 1983

LITHOBID

NDA NDA018027

Mar 26, 1984

LITHOBID

NDA NDA018027

Mar 26, 1985

LITHOBID

NDA NDA018027

May 29, 1985

LITHOBID

NDA NDA018027

May 1, 1986

LITHOBID

NDA NDA018027

Aug 24, 1988

LITHOBID

NDA NDA018027

Oct 13, 1988

LITHOBID

NDA NDA018027

Oct 13, 1988

LITHOBID

NDA NDA018027

Apr 7, 1989

LITHOBID

NDA NDA018027

Apr 20, 1990

LITHOBID

NDA NDA018027

May 2, 1990

LITHOBID

NDA NDA018027

May 26, 1995

LITHOBID

NDA NDA018027

Jul 11, 1997

LITHOBID

NDA NDA018027

Dec 22, 2000

LITHOBID

NDA NDA018027

Oct 16, 2001

LITHOBID

NDA NDA018027

Oct 7, 2002

LITHOBID

NDA NDA018027

Oct 7, 2002

LITHOBID

NDA NDA018027

Oct 7, 2002

LITHOBID

NDA NDA018027

Oct 7, 2002

LITHOBID

NDA NDA018027

Oct 7, 2002

LITHOBID

NDA NDA018027

Oct 7, 2002

LITHOBID

NDA NDA018027

Apr 7, 2006

LITHOBID

NDA NDA018027

Oct 1, 2006

LITHOBID

NDA NDA018027

Oct 20, 2011

LITHOBID

NDA NDA018027

Jan 5, 2015

LITHOBID

NDA NDA018027

May 11, 2015

LITHOBID

NDA NDA018027

May 27, 2016

LITHOBID

NDA NDA018027

Apr 30, 2018

LITHOBID

NDA NDA018027

Dec 20, 2018

LITHOBID

NDA NDA018027

Feb 5, 2020

LITHOBID

NDA NDA018027

Oct 13, 2022

LITHOBID

NDA NDA018027

Sources

References

[1]
ClinicalTrials.gov — 91 trial records for Lithium. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Lithobid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Lithium compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Lithium. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA018027). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Solvay Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: SSolvay Pharmaceuticals

Lithobid

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q3 2028

Q3 2033

Trials by Indication[1]

Bipolar Disorder20 trials

Depression7 trials

Bipolar I Disorder4 trials

Treatment Resistant Depression4 trials

Mood Disorder3 trials

Major Depression3 trials

Bipolar Depression2 trials

Suicide2 trials

CAR2 trials

Fasting Conditions2 trials

Cognitive impairment2 trials

Treatment2 trials

Phase 11 trial

First-line Treatment1 trial

Aripiprazole1 trial

Randomised Controlled Trial1 trial

Amyotrophic Lateral Sclerosis1 trial

Depressive Disorder1 trial

Combination Therapy1 trial

Tics1 trial

Agitation1 trial

Alzheimer's Disease1 trial

Prevention1 trial

Conduct Disorder1 trial

Maintenance Treatment1 trial

Huntington's Disease1 trial

Suicidality1 trial

TIA1 trial

Function1 trial

Long COVID1 trial

Major Depressive Disorder1 trial

Effectiveness1 trial

Parkinson's Disease1 trial

Drug Therapy1 trial

Progressive Supranuclear Palsy1 trial

Adult1 trial

Metabolism1 trial

Colorectal Cancer1 trial

Acceptability1 trial

Osteoporosis-Pseudoglioma Syndrome1 trial

ESS1 trial

Olanzapine1 trial

Small Cell Lung Cancer1 trial

Mania1 trial

Depression, Bipolar1 trial

Unspecified5 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News